These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38773162)

  • 1. Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin.
    Kosum P; Siranart N; Nissaipan K; Laohapiboolrattana W; Sowalertrat W; Triamamornwooth K; Arunphan R; Sriyom A; Rungpradubvong V
    Sci Rep; 2024 May; 14(1):11647. PubMed ID: 38773162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia.
    Bernaitis N; Badrick T; Davey AK; Anoopkumar-Dukie S
    Intern Med J; 2016 Aug; 46(8):925-31. PubMed ID: 27040159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.
    Urbonas G; Valius L; Šakalytė G; Petniūnas K; Petniūnienė I
    Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30650565
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients.
    Tomita H; Kadokami T; Momii H; Kawamura N; Yoshida M; Inou T; Fukuizumi Y; Usui M; Funakoshi K; Yamada S; Aomori T; Yamamoto K; Uno T; Ando S;
    Thromb Res; 2013 Nov; 132(5):537-42. PubMed ID: 24071466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
    Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.
    Liu S; Singer A; McAlister FA; Peeler W; Heran BS; Drummond N; Manca DP; Allan GM; Korownyk C; Kolber MR; Greiver M; Garrison SR
    Can Fam Physician; 2019 Jun; 65(6):416-425. PubMed ID: 31189630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
    Williams BA; Evans MA; Honushefsky AM; Berger PB
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin.
    Huang D; Wong CL; Cheng KW; Chan PH; Yue WS; Wong CK; Ho CW; Wong ICK; Chan EW; Siu CW
    Postgrad Med J; 2018 Apr; 94(1110):207-211. PubMed ID: 29459408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
    JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial.
    Aktan A; Güzel T; Aslan B; Kılıç R; Günlü S; Özbek M; Arslan B; Demir M; Ertaş F
    Kardiol Pol; 2023; 81(2):132-140. PubMed ID: 36594528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation.
    Chan YH; Lee KT; Kao YW; Huang CY; Chen YL; Hang SC; Chu PH
    PLoS One; 2019; 14(3):e0213517. PubMed ID: 30883567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor.
    Vanerio G
    J Stroke Cerebrovasc Dis; 2015 Oct; 24(10):2223-8. PubMed ID: 26232891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.